Former Deputy Director of Public Citizen’s Health Research Group
Con to the question "Should Prescription Drugs Be Advertised Directly to Consumers?"
"Like all interventions in health care, DTC advertising should be evaluated by comparing risks and benefits in the context of available or potentially available alternatives. On balance, we believe that the clearly demonstrated adverse effects of DTC advertising outweigh the still undemonstrated effects that might be beneficial. Where there is any hint of a beneficial effect, we find that there are better ways of accomplishing it...
[D]irect-to-consumer advertisements bear little relationship to public health needs. New and expensive drugs, those for diseases that are bothersome and incurable, are the ones that we see advertised. Only 14 percent of sales for the top 50 DTC-advertised drugs are for acute conditions, and only one of the top 50 DTC-advertised drugs was an antibiotic, presumably because people are quickly cured and there is no need for a refill...
[T]he price of health care is being driven up. Patients are being induced to request new, more expensive medications instead of equally effective, older generic ones."
Testimony, US Senate Special Committee On Aging titled "The Ipact of Direct to Consumer Drug Advertising on Senior's Health and Health Care Costs," www.aging.senate.gov, Sep. 29, 2005
Experts Individuals with MDs, DOs, PhDs, MPHs, or equivalent advanced degrees in fields relevant to pharmaceutical drugs and public health; top-level federal government officials significantly involved in issues related to prescription drug advertising. [Note: Experts definition varies by site.]
Involvement and Affiliations:
Advisor, Office of Policy, US Food and Drug Administration (FDA)
Former Deputy Director, Public Citizen's Health Research Group
Former Assistant Research Scientist, Institute for Social Research
Former Assistant Professor, Department of Family and Community Medicine, University of California, San Francisco
Former Professor, University of Michigan
Former Member, FDA’s Transmissible Spongiform Encephalopathy Advisory Committee
Completed residencies in Family Practice at the University of California at San Francisco and in Preventive Medicine at the University of California at Berkeley
MPH, University of California at Berkeley
MD, Albert Einstein College of Medicine
Phone: 301-796-4830 (FDA Office of Policy) Fax: 301-847-3541 (FDA Office of Policy) Email: None found Website:FDA Office of Policy
"DTC Advertising Harms Patients and Should Be Tightly Regulated," Journal of Law, Medicine & Ethics, Sep. 2009
"An Economic Analysis of Needle Exchange and Pharmacy-Based Programs to Increase Sterile Syringe Availability for Injection Drug Users," Journal of Acquired Immune Deficiency Syndromes and Human Retroviruses, 1997